The year 2018 has been a mixed year for Indian pharma stocks. Price pressure may have eased in the US, but other challenges, especially the Chinese API supply, have emerged. American regulator USFDA is still hot on the heels of many companies.

Who better than Saion Mukherjee, managing Director and head of equity research at Nomura, to shed light on these vital topics. He also breaks down pharma earnings, the most important current and future trends and stocks.

Tune in right away!